Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform

References

• Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs. 2019 Feb;11(2):219–12. doi:https://doi.org/10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. mAbs. 2020 Jan;12(1):1703531. doi:https://doi.org/10.1080/19420862.2019.1703531.
   PubMed Web of Science ®Google Scholar
• Krah S, Kolmar H, Becker S, Zielonka S. Engineering IgG-like bispecific antibodies—an overview. Antibodies. 2018 Aug;7(3):28. doi:https://doi.org/10.3390/antib7030028.
   Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu -R-R, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007 Nov;25(11):1290–97. doi:https://doi.org/10.1038/nbt1345.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585–608.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017 Feb;9(2):182–212. doi:https://doi.org/10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Könning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, Schröter C, Sellmann C, Hock B, Kolmar H, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017 Aug;45:10–16. doi:https://doi.org/10.1016/j.sbi.2016.10.019.
   PubMed Web of Science ®Google Scholar
• Zielonka S, Empting M, Grzeschik J, Könning D, Barelle CJ, Kolmar H. Structural insights and biomedical potential of IgNAR scaffolds from sharks. mAbs. 2015 Jan;7(1):15–25. doi:https://doi.org/10.4161/19420862.2015.989032.
   PubMed Web of Science ®Google Scholar
• Li Z, Krippendorff B-F, Sharma S, Walz AC, Lavé T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs. 2016;8(1):113–19. doi:https://doi.org/10.1080/19420862.2015.1111497.
   PubMed Web of Science ®Google Scholar
• Sellmann C, Pekar L, Bauer C, Ciesielski E, Krah S, Becker S, Toleikis L, Kügler J, Frenzel A, Valldorf B, et al. A one-step process for the construction of phage display scFv and VHH libraries. Mol Biotechnol. 2020 Jan;62(4):228–39. doi:https://doi.org/10.1007/s12033-020-00236-0.
   PubMed Web of Science ®Google Scholar
• Uchański T, Zögg T, Yin J, Yuan D, Wohlkönig A, Fischer B, Rosenbaum DM, Kobilka BK, Pardon E, Steyaert J, et al. An improved yeast surface display platform for the screening of nanobody immune libraries. Sci Rep. 2019 Dec;9(1). doi:https://doi.org/10.1038/s41598-018-37212-3.
   PubMedGoogle Scholar
• Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlkönig A, Ruf A, Muyldermans S, Hol WGJ, Kobilka BK, Steyaert J, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014 Mar;9(3):674–93. doi:https://doi.org/10.1038/nprot.2014.039.
   PubMed Web of Science ®Google Scholar
• Krah S, Schröter C, Zielonka S, Empting M, Valldorf B, Kolmar H. Single-domain antibodies for biomedical applications. Immunopharmacol Immunotoxicol. 2016;38(1):21–28. doi:https://doi.org/10.3109/08923973.2015.1102934.
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020 Feb;34(1):11-26. doi: https://doi.org/10.1007/s40259-019-00392-z
   Google Scholar
• Duggan S. Caplacizumab: first Global Approval. Drugs. 2018 Oct;78(15):1639–42. doi:https://doi.org/10.1007/s40265-018-0989-0.
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017 Nov;8. doi:https://doi.org/10.3389/fimmu.2017.01603.
   PubMed Web of Science ®Google Scholar
• Chanier T, Chames P. Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer. Antibodies. 2019 Jan;8(1):13. doi:https://doi.org/10.3390/antib8010013.
   Web of Science ®Google Scholar
• Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pelegrin A, Chames P, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting Fc RIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther. 2013 Aug;12(8):1481–91. doi:https://doi.org/10.1158/1535-7163.MCT-12-1012.
   PubMed Web of Science ®Google Scholar
• Turini M, Chames P, Bruhns P, Baty D, Kerfelec B. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget. 2014 Jul;5(14):5304–19. doi:https://doi.org/10.18632/oncotarget.2093.
   PubMedGoogle Scholar
• Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, Chames P, Baty D, Kerfelec B. A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer. Front Immunol. 2019 Jul;10. doi:https://doi.org/10.3389/fimmu.2019.01593.
   Google Scholar
• Scapin G, Yang X, Prosise WW, McCoy M, Reichert P, Johnston JM, Kashi RS, Strickland C. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015 Dec;22(12):953–58. doi:https://doi.org/10.1038/nsmb.3129.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Eng Des Sel. 2010 Apr;23(4):195–202. doi:https://doi.org/10.1093/protein/gzp094.
   PubMed Web of Science ®Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, van Bergen En Henegouwen PMP, Ferguson KM. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013 Jul;21(7):1214–24. doi:https://doi.org/10.1016/j.str.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Roth L, Krah S, Klemm J, Günther R, Toleikis L, Busch M, Becker S, Zielonka S. Isolation of antigen-specific VHH single-domain antibodies by combining animal immunization with yeast surface display. Methods Mol Biol. 2020;2070:173–89.
   PubMedGoogle Scholar
• Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. mAbs. 2016 May;8(4):828–38. doi:https://doi.org/10.1080/19420862.2016.1160192.
   PubMed Web of Science ®Google Scholar
• Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. Mole Ther. 2017 Feb;25(2):523–33. doi:https://doi.org/10.1016/j.ymthe.2016.11.006.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015 Jun;125(26):4024–31. doi:https://doi.org/10.1182/blood-2014-12-614636.
   PubMed Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, et al. Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015 May;7(287):287ra70–287ra70. doi:https://doi.org/10.1126/scitranslmed.aaa4802.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014 Nov;6(261):261ra154–261ra154. doi:https://doi.org/10.1126/scitranslmed.3009835.
   PubMed Web of Science ®Google Scholar
• Khan SN, Sok D, Tran K, Movsesyan A, Dubrovskaya V, Burton DR, Wyatt RT. Targeting the HIV-1 spike and coreceptor with Bi- and trispecific antibodies for single-component broad inhibition of entry. J Virol. 2018 Jul;92(18). doi:https://doi.org/10.1128/JVI.00384-18
   Google Scholar
• Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009 Jan;284(5):3273–84. doi:https://doi.org/10.1074/jbc.M806889200.
   PubMed Web of Science ®Google Scholar
• Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. mAbs. 2016 Apr;8(3):562–73. doi:https://doi.org/10.1080/19420862.2016.1147640.
   PubMed Web of Science ®Google Scholar
• Croasdale R, Wartha K, Schanzer JM, Kuenkele K-P, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, et al. Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys. 2012 Oct;526(2):206–18. doi:https://doi.org/10.1016/j.abb.2012.03.016.
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig TM) molecules. mAbs. 2009 Aug;1(4):339–47. doi:https://doi.org/10.4161/mabs.1.4.8755.
   PubMed Web of Science ®Google Scholar
• Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019 Jun;177(7):1701–1713.e16. doi:https://doi.org/10.1016/j.cell.2019.04.041.
   PubMed Web of Science ®Google Scholar
• Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget. 2015 Oct;6(31):32075–88. doi:https://doi.org/10.18632/oncotarget.5135.
   PubMedGoogle Scholar
• Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. 2013 Apr;9(4):527–39. doi:https://doi.org/10.2217/fon.12.203.
   PubMed Web of Science ®Google Scholar
• DiGiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, Lake MR, Greischar AJ, Liu J, Ghayur T. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. mAbs. 2011 Sep;3(5):487–94. doi:https://doi.org/10.4161/mabs.3.5.16326.
   PubMed Web of Science ®Google Scholar
• Mayer K, Baumann A-L, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U. TriFabs—trivalent IgG-shaped bispecific antibody derivatives: design, generation, characterization and application for targeted payload delivery. Int J Mol Sci. 2015 Nov;16(11):27497–507. doi:https://doi.org/10.3390/ijms161126037.
   PubMed Web of Science ®Google Scholar
• Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel. 2012 Oct;25(10):571–80. doi:https://doi.org/10.1093/protein/gzs064.
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Zemla A, Wilson IA, Rupp B. Antibody elbow angles are influenced by their light chain class. J Mol Biol. 2006 Apr;357(5):1566–74. doi:https://doi.org/10.1016/j.jmb.2006.01.023.
   PubMed Web of Science ®Google Scholar